Cytek Biosciences [CTKB] vs Conmed [CNMD] Detailed Stock Comparison
Cytek Biosciences
NASDAQ
Loading...
Conmed
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Cytek Biosciences wins in 4 metrics, Conmed wins in 13 metrics, with 0 ties. Conmed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cytek Biosciences | Conmed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 374.50 | 14.42 | Conmed |
| Price-to-Book Ratio | 1.31 | 1.58 | Cytek Biosciences |
| Debt-to-Equity Ratio | 3.95 | 87.93 | Cytek Biosciences |
| PEG Ratio | 64.83 | 10.55 | Conmed |
| EV/EBITDA | -11.27 | 11.38 | Cytek Biosciences |
| Profit Margin (TTM) | -3.27% | 8.31% | Conmed |
| Operating Margin (TTM) | -23.30% | 10.62% | Conmed |
| EBITDA Margin (TTM) | N/A | 10.62% | N/A |
| Return on Equity | -1.67% | 11.69% | Conmed |
| Return on Assets (TTM) | -3.77% | 4.03% | Conmed |
| Free Cash Flow (TTM) | $21.65M | $153.88M | Conmed |
| Dividend Yield | N/A | 1.15% | N/A |
| 1-Year Return | -22.80% | -18.50% | Conmed |
| Price-to-Sales Ratio (TTM) | 2.51 | 1.19 | Conmed |
| Enterprise Value | $247.79M | $2.50B | Conmed |
| EV/Revenue Ratio | 1.26 | 1.89 | Cytek Biosciences |
| Gross Profit Margin (TTM) | 48.62% | 55.01% | Conmed |
| Revenue per Share (TTM) | $2 | $43 | Conmed |
| Earnings per Share (Diluted) | $-0.09 | $3.54 | Conmed |
| Beta (Stock Volatility) | N/A | 1.17 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cytek Biosciences vs Conmed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cytek Biosciences | -1.95% | 10.71% | 17.49% | 6.33% | -21.75% | -38.66% |
| Conmed | 2.42% | 4.55% | 4.23% | -5.33% | -18.79% | -18.83% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cytek Biosciences | -22.80% | -72.95% | -78.52% | -78.52% | -78.52% | -78.52% |
| Conmed | -18.50% | -47.01% | -35.81% | -2.51% | 178.31% | 88.29% |
Performance & Financial Health Analysis: Cytek Biosciences vs Conmed
| Metric | CTKB | CNMD |
|---|---|---|
| Market Information | ||
| Market Cap | $492.70M | $1.58B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,272,570 | 560,860 |
| 90 Day Avg. Volume | 1,073,943 | 501,800 |
| Last Close | $4.03 | $54.67 |
| 52 Week Range | $2.37 - $7.63 | $46.00 - $78.19 |
| % from 52W High | -47.18% | -30.08% |
| All-Time High | $28.70 (Sep 13, 2021) | $159.11 (Nov 01, 2021) |
| % from All-Time High | -85.96% | -65.64% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.03% |
| Quarterly Earnings Growth | -0.08% | -0.29% |
| Financial Health | ||
| Profit Margin (TTM) | -0.03% | 0.08% |
| Operating Margin (TTM) | -0.23% | 0.11% |
| Return on Equity (TTM) | -0.02% | 0.12% |
| Debt to Equity (MRQ) | 3.95 | 87.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.97 | $32.41 |
| Cash per Share (MRQ) | $2.06 | $1.10 |
| Operating Cash Flow (TTM) | $15.20M | $165.21M |
| Levered Free Cash Flow (TTM) | $26.66M | $163.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.15% |
| Last 12-Month Dividend | N/A | $0.60 |
Valuation & Enterprise Metrics Analysis: Cytek Biosciences vs Conmed
| Metric | CTKB | CNMD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 374.50 | 14.42 |
| Forward P/E | 64.83 | 10.55 |
| PEG Ratio | 64.83 | 10.55 |
| Price to Sales (TTM) | 2.51 | 1.19 |
| Price to Book (MRQ) | 1.31 | 1.58 |
| Market Capitalization | ||
| Market Capitalization | $492.70M | $1.58B |
| Enterprise Value | $247.79M | $2.50B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.26 | 1.89 |
| Enterprise to EBITDA | -11.27 | 11.38 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.17 |
| Book Value per Share (MRQ) | $2.97 | $32.41 |
Financial Statements Comparison: Cytek Biosciences vs Conmed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CTKB | CNMD |
|---|---|---|
| Revenue/Sales | $41.46M | $321.26M |
| Cost of Goods Sold | $21.30M | $143.50M |
| Gross Profit | $20.16M | $177.75M |
| Research & Development | $9.73M | $12.95M |
| Operating Income (EBIT) | $-14.98M | $15.96M |
| EBITDA | $-8.09M | $34.21M |
| Pre-Tax Income | $-11.27M | $7.67M |
| Income Tax | $136,000 | $1.64M |
| Net Income (Profit) | $-11.40M | $6.04M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CTKB | CNMD |
|---|---|---|
| Cash & Equivalents | $95.30M | $35.49M |
| Total Current Assets | $380.50M | $639.00M |
| Total Current Liabilities | $67.69M | $283.15M |
| Long-Term Debt | $8.37M | $891.44M |
| Total Shareholders Equity | $379.62M | $977.64M |
| Retained Earnings | $-46.60M | $560.13M |
| Property, Plant & Equipment | $21.62M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CTKB | CNMD |
|---|---|---|
| Operating Cash Flow | $3.22M | $49.72M |
| Capital Expenditures | $-816,000 | $-3.78M |
| Free Cash Flow | $-976,000 | $37.76M |
| Debt Repayment | $-1.52M | $-180.59M |
| Common Stock Repurchase | $-10.63M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CTKB | CNMD |
|---|---|---|
| Shares Short | 5.65M | 2.11M |
| Short Ratio | 4.54 | 4.86 |
| Short % of Float | 0.06% | 0.09% |
| Average Daily Volume (10 Day) | 1,272,570 | 560,860 |
| Average Daily Volume (90 Day) | 1,073,943 | 501,800 |
| Shares Outstanding | 129.21M | 30.90M |
| Float Shares | 108.71M | 30.68M |
| % Held by Insiders | 0.09% | 0.01% |
| % Held by Institutions | 0.60% | 1.17% |
Dividend Analysis & Yield Comparison: Cytek Biosciences vs Conmed
| Metric | CTKB | CNMD |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.60 |
| Last 12-Month Dividend Yield | N/A | 1.15% |
| 3-Year Avg Annual Dividend | N/A | $0.73 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $2.20 |
| Ex-Dividend Date | N/A | Mar 14, 2025 |